USPTO serial 90326590
IMMUNOCHARGING
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SCHMIDT, JOHN JOSEPH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IMMUNOCHARGING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Florham Park, NJ
Florham Park, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
Camille M. Miller COZEN O'CONNORONE LIBERTY PLACE1650 MARKET STREET, SUITE 2800PHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research | ACTIVE | — |
| 005 | Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, umbilical cord cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; surgical implants comprised of living tissue, namely, human amniotic membrane and human chorionic membrane intended for subsequent implantation; surgical implants comprised of living tissue, namely, human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use in the nature of biological preparations, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for treating cancer or other disease-associated antigen; pharmaceutical preparations for wounds, namely, biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; written instructional materials distributed in connection with the aforesaid goods packaged with the goods; biological products for medical use, namely, biological preparations in the nature of placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for treatment of cancer or other disease-associated antigen | ACTIVE | — |
| 042 | Research, development and testing services for others in the fields of genomics, biotechnology and pharmaceuticals; stem cell research services; research, development and testing services in the fields of genomics, biotechnology and pharmaceuticals, namely, collection, testing, processing, preservation, storage and retrieval of cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; laboratory research services in the field of genomics, biotechnology and pharmaceuticals consisting of collection, testing, processing, preservation, storage and retrieval of bioengineered cells, human allograft tissue made from human umbilical cords and human placentas, human amniotic membrane and human chorionic membrane, human collagen and extracellular matrix compositions; providing technical writing and a website featuring information in the field of medical research relating to banking stem cells and cord blood banking; biological research, namely, biosourcing of clinically accessible, immune-tolerant human stem and progenitor and other postpartum placenta-derived cell populations and tissues for medical research; medical research to find methods to restore the structure and function of damaged or diseased tissues and organs, including wound care, reconstructive medicine, whole organ and tissue regeneration and renewal; medical research regarding emergent cell therapies; medical research regarding allogeneic immunotherapy; providing on-line information, news and commentary in the field of medical research relating to the foregoing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celularity Inc.
- Other trademarks owned by Celularity Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named IMMUNOCHARGING
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 5, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 4, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 29, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 27, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 27, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 27, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 7, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 5, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 5, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 5, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 5, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 3, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 3, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 3, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 3, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 8, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 8, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 19, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 3, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 30, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 21, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2020 | NWAP | NEW APPLICATION ENTERED | — |